AstraZeneca Phase III DANUBE Trial in Bladder Cancer Didn't Meet End Point
March 06 2020 - 2:44AM
Dow Jones News
By Joe Hoppe
AstraZeneca PLC said Friday that the third phase of the DANUBE
trial for its bladder cancer drugs, Imfinzi and Imfinzi plus
tremelimumab, failed to meet the endpoints of the test.
The FTSE 100-listed drug maker said that the new treatments
failed to improve the overall survival of patients with tumor cells
with high levels of the protein PD-L1, when compared to those who
were provided standard chemotherapy.
Imfinzi will be further tested in patients with earlier stages
of bladder cancer, in the Phase III NIAGARA trial and in the Phase
III POTOMAC trial.
"The results from this trial will inform our comprehensive Phase
III development programme in bladder cancer," said Executive Vice
President José Baselga. "We look forward to the results of the
Phase III NILE trial also in the 1st-line metastatic setting, and
we continue to advance clinical trials for patients at earlier
stages of the disease."
In 2018, approximately 550,000 people were diagnosed with
bladder cancer around the world and 200,000 died from the
disease.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
March 06, 2020 02:29 ET (07:29 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From May 2023 to May 2024
